Potential biomarkers for retinopathy of prematurity identified by circular RNA profiling in peripheral blood mononuclear cells

Yun Li1,2, Haixiang Zhou1,2, Qian Huang1,2, Wei Tan1,2, Yuting Cai1,2, Zicong Wang1,2, Jingling Zou1,2, Bingyan Li1,2, Shigeo Yoshida3 and Yedi Zhou1,2*

1Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha, China, 2Hunan Clinical Research Center of Ophthalmic Disease, Changsha, China, 3Department of Ophthalmology, Kurume University School of Medicine, Kurume, Japan

Purpose: This study aims to reveal the altered expression profiles of circular RNAs (circRNAs) in the peripheral blood mononuclear cells (PBMCs) of patients with retinopathy of prematurity (ROP), and to identify potential biomarkers for ROP diagnosis.

Methods: Differentially expressed circRNAs in PBMCs of five infants with ROP and five controls were identified using microarray analysis. Twelve altered circRNAs were validated using reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR). Bioinformatic analyses were conducted to predict the circRNA/miRNA interactions, competing endogenous RNA (ceRNA) network, related biological functions, and signaling pathways. Four selected circRNAs in PBMCs were verified using RT-qPCR in another cohort, including 24 infants with ROP and 23 premature controls, and receiver operating characteristic (ROC) curves were used to estimate their potential as diagnostic biomarkers of ROP.

Results: A total of 54 and 143 circRNAs were significantly up- and down-regulated, respectively, in the PBMCs of patients with ROP compared with controls. Twelve of the significantly altered circRNAs were preliminarily validated by RT-qPCR, which confirmed the reliability of the microarray analysis. The circRNA/miRNA interactions and ceRNA network were displayed according to the altered circRNAs. Three circRNAs (hsa_circRNA_061346, hsa_circRNA_092369, and hsa_circRNA_103554) were identified as potential diagnostic biomarkers for ROP with certain clinical values.

Conclusions: CircRNAs were significantly altered in PBMCs of treatment-requiring ROP patients. CircRNAs may be used as potential biomarkers and possible therapeutic targets for ROP.
Introduction

Retinopathy of prematurity (ROP) is a major complication of premature birth and has become a significant problem with improved survival in premature infants (1). Severe cases of ROP may lead to long-term vision loss, and consistent with this ROP is a major cause of childhood blindness (2) so there is an urgent need to facilitate its diagnosis and treatment.

The diagnosis of ROP is usually based on fundus screening with binocular indirect ophthalmoscopy and/or a wide-field digital retinal imaging system (such as the RetCam digital retinal camera) (3). This screening method has low efficiency and a high rate of misdiagnosis, and associated treatment decisions are sometimes not objective. Thus, sensitive and specific biomarkers are needed for the diagnosis and assessment of prognosis in ROP (4).

While anti-vascular endothelial growth factor (VEGF) therapy and laser photoocoagulation are effective and are used clinically for ROP treatment (5, 6), they have limitations (such as the requirement for repeated treatment) and are costly. Therefore, to identify novel therapeutic targets it is important to enhance understanding of the regulatory mechanisms of ROP pathogenesis.

As a novel class of endogenous non-coding RNAs, circular RNA (circRNA) has a closed structure without 5' caps and 3' poly-A ends (7), and is thus more stable than linear RNA (8). Therefore, circRNAs have great potential to be biomarkers in various diseases (9-11). Though incapable of coding proteins, circRNA functions as a molecular sponge by targeting microRNAs (miRNAs) and modulates mRNA expression by competing endogenous RNA (ceRNA) mechanisms (12, 13).

Previous studies have indicated that circRNAs have great potential for application in retinal disorders (14) including as diagnostic biomarkers for diabetic retinopathy (15, 16), retinoblastoma (17) and age-related macular degeneration (18). They are also considered to be therapeutic targets for retinal neovascular disease. For example, 26 differentially expressed circRNAs were identified in serum exosomes of patients with proliferative diabetic retinopathy, and a novel circRNA derived from high-glucose-induced endothelial cells, circFndc3b, has a regulatory role in angiogenesis (19). Yao et al. (20) also reported an anti-angiogenesis effect by targeting circRNA-MET via attenuation of endothelial tip cell specialization, while Deng et al. (21) demonstrated that CircPDE4B suppresses retinal pathological angiogenesis by sponging miR-181c and facilitating the ubiquitin degradation of HIF-1α. Despite these findings, the role played by circRNAs in regulating retinal neovascularization remains unclear.

We previously showed the altered expression profiles of circRNAs in a mouse model of oxygen-induced retinopathy (OIR) (22), which parallels the pathogenesis of ROP to some extent. However, circRNAs are tissue-, disease-, and species-specific (23), so further exploration is needed using clinical ROP samples.

An increasing number of studies have shown that ocular diseases are closely associated with the regulation of the systemic immune system. Silveira et al. revealed the relationship between up-regulated plasma levels of several cytokines (IL-6, IL-8, and TNF-α) at birth with the later development of treatment-requiring ROP (24). Gao et al. indicated that peripheral macrophage depletion significantly inhibits pathological retinal neovascularization in OIR model in mice (25). Activation of mononuclear phagocytes may participate in the pathogenesis and development of ischemic retinopathies including ROP, which provide a new promising target in preventing these diseases (26). As the key drivers of immune responses, peripheral blood mononuclear cells (PBMCs) are comprised of variety types of immune cells, such as lymphocytes (T cells, B cells and natural killer cells), monocytes and dendritic cells (27). PBMCs are widely used for transcriptomics analyses in clarifying the immunological mechanisms in different diseases (27). For example, circRNA expression profiles in PBMCs were revealed in patients with rheumatoid arthritis (9), multiple sclerosis (28) and systemic lupus erythematosus (29), which identified potential biomarkers and predicted possible immunological mechanisms of these diseases.

The aim of this study was to identify novel potential biomarkers and possible molecular targets. We conducted microarray analysis with verification by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) in the PBMCs of patients with ROP. The potential values of the altered circRNAs were assessed in an expanded cohort, and further bioinformatic analyses were performed to identify those possibly involved in biological functions and signaling pathways.

Materials and methods

Study subjects

In total, 57 preterm newborns were included in this study between December 2020 and January 2022 at the Second
Xiangya Hospital of Central South University, Changsha, China. Among them, 29 infants had a diagnosis of ROP and required therapeutic treatment (five for screening and 24 for validation) according to the International Classification of Retinopathy of Prematurity protocol (30). The remaining 28 preterm newborns without retinopathy were enrolled as controls (five for screening and 23 for validation). The study subjects were recruited with exclusion criteria as reported (31). Blood was collected prior to treatment. For ethical reasons, to avoid additional blood draw, samples were collected from the control group at their last blood draw before leaving the neonatal intensive care unit. The study protocol was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from the participants’ guardians. The clinical characteristics of the included subjects are summarized in Table 1.

Preparation of PBMCs and RNA isolation

1.0–1.5 ml of venous blood from each study subject was collected in an anticoagulant tube (Ethylene Diamine Tetraacetic Acid) in the morning and was taken to the laboratory within 2 h. PBMCs were isolated from the blood by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, NJ, USA). Total RNAs were extracted using TRIzol reagent (Invitrogen, Carlsbad, USA), and the samples were stored at -80°C. The NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE, USA) was used to measure the concentrations. The RNA integrity was assessed by electrophoresis on a denaturing agarose gel.

Microarray analysis of circRNAs

Five infants with ROP needing treatment and five controls were included for the microarray analysis which was conducted as previously described (9). In brief, prepared total RNAs were treated with Rnase R (Epicentre, Madison, WI, USA) to enrich circRNAs, and were then amplified and transcribed into fluorescent cRNA using random primer and an Arraystar Super RNA Labeling Kit (Arraystar, Rockville, MD, USA). The labeled cRNAs were hybridized onto the Arraystar Human circRNA Arrays V2 (8x15K, Arraystar), and incubated in an Agilent Hybridization Oven. After washing, the slide scanning was conducted by using the Agilent Scanner G2505C. The images were analyzed using Agilent Feature Extraction software (version 11.0.1.1). The criterion for significant alteration of circRNAs was ≥2-fold increase or decrease and \( P<0.05 \). The circRNA microarray analysis raw data were deposited in the Gene Expression Omnibus database (Accession No. GSE204780).

RT-qPCR

To validate the results of microarray analysis, RT-qPCR was performed as previously described (32) with slight modification. In brief, total RNAs were transcribed into cDNAs using the SuperScript III Reverse Transcriptase kit (Invitrogen, Carlsbad, CA, USA). RT-qPCR was performed using a QuantStudio5 Real-time PCR System (Applied Biosystems, Foster City, CA, USA) with 2× PCR Master Mix (Arraystar). The sequences of the primers are listed in Table 2. The relative expression level of circRNAs were normalized to those of \( \beta\)-actin.

Bioinformatics analysis

Predictions of circRNA-miRNA interactions were conducted using Arraystar’s miRNA target prediction software according to TargetScan and miRanda. The circRNA-miRNA-mRNA network was constructed according to the competing endogenous RNA (ceRNA) hypothesis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were used for further predictions of involvement in biological functions and signaling pathways.

TABLE 1 Clinical characteristics of the individuals included in this study.

| Characteristics                        | Screening cohort | Validation cohort |
|----------------------------------------|------------------|-------------------|
|                                        | Control n=5      | ROP n=5           | P-value | Control n=23 | ROP n=24 | P-value |
| Gestational age, mean ± SD, weeks      | 30.94 ± 1.09     | 28.29 ± 2.08      | 0.035   | 31.24 ± 1.28 | 28.54 ± 2.43 | <0.001 |
| Birth weight, mean ± SD, g             | 1314.00 ± 121.16 | 1080.00 ± 258.84  | 0.105   | 1454.78 ± 263.58 | 1137.50 ± 379.65 | 0.002  |
| Postmenstrual age at blood draw, mean ± SD, weeks | 37.26 ± 0.16     | 37.83 ± 0.89      | 0.195   | 36.68 ± 1.52 | 39.99 ± 3.68 | <0.001 |
| Body weight at blood draw, mean ± SD, g | 2236.00 ± 119.29 | 2252.00 ± 113.67  | 0.834   | 2247.61 ± 266.03 | 2810.83 ± 960.63 | 0.012  |
| Sex (male/female)                      | 1/4              | 3/2               | 0.197   | 9/14          | 12/12     | 0.454   |

SD, standard deviation; ROP, retinopathy of prematurity.
Statistical analysis

Numeric variables were compared using a Student’s t-test or Mann-Whitney U-test, and categorical variables were compared using a Chi-square test. P<0.05 was considered statistically significant. Moreover, to adjust for multiple comparisons, FDR (false discovery rate) is calculated with Benjamini-Hochberg method.

Results

Expression profiling of circRNAs in PBMCs from patients with ROP

As demonstrated by the box plot (Figure 1A), all samples showed stable and similar distributions of circRNA profiles. Variations in the expressed circRNAs are indicated by a scatter plot (Figure 1B) and a volcano plot (Figure 1C), and differentially expressed circRNAs were identified and classified as shown by the heatmap (Figure 1D). Using a threshold value of ≥2-fold change and P<0.05, a total of 54 circRNAs were significantly up-regulated and 143 circRNAs were down-regulated in the PBMC samples of patients with ROP compared to the controls. Among them, two up-regulated and 19 down-regulated circRNAs met FDR<0.05. The top 10 up- and down-regulated circRNAs are summarized in Table 3, with hsa_circRNA_008200 and hsa_circRNA_020959 showing the greatest increase or decrease, respectively.

GO enrichment and KEGG pathway analyses of the significantly altered circRNAs

The results of GO analysis showed that the host genes of the up-regulated circRNAs were most enriched in the “cell surface receptor signaling pathway”, “nuclear speck” and “kinase binding” (Figure 2A), and those of the down-regulated circRNAs were most enriched in “oxygen transport”, “cytosol” and “haptoglobin binding” (Figure 2B). Meanwhile, KEGG pathway analysis indicated that the up- and down-regulated circRNAs may be involved in “Fc gamma R-
FIGURE 1
Expression profile of circRNAs in retinopathy of prematurity (ROP) patients and controls. (A) A box plot shows the expression profile of circRNAs in each blood sample after normalization. (B) Raw variations of the circRNA expression profile are displayed on a scatter plot. (C) A volcano plot shows significantly altered circRNAs using a threshold of ≥2-fold change and P<0.05. (D) Heatmap derived from hierarchical cluster analysis showing different expressions of circRNAs in each sample.
### Table 3: Top 10 up- and down-regulated circRNAs identified by microarray analysis in peripheral blood mononuclear cells (PBMCs) of infants with retinopathy of prematurity (ROP) compared with premature controls.

| circRNA          | chrom | circRNA_type | GeneSymbol | FC (abs) | Regulation | P-value | FDR       |
|------------------|-------|--------------|------------|----------|------------|---------|-----------|
| hsa_circRNA_088200 | chr9  | exonic       | TNC        | 3.256831 | up         | 0.002593| 0.136782 |
| hsa_circRNA_091000 | chrX  | exonic       | NONO       | 2.835938 | up         | 0.001744| 0.124536 |
| hsa_circRNA_081175 | chr7  | exonic       | LIMK1      | 2.820852 | up         | 0.018692| 0.255727 |
| hsa_circRNA_105034 | chrX  | exonic       | AFF2       | 2.800486 | up         | 0.037582| 0.310382 |
| hsa_circRNA_092368 | chr1  | sense overlapping | CNN3     | 2.783987 | up         | 0.004532| 0.164641 |
| hsa_circRNA_071935 | chr5  | exonic       | TRIO       | 2.467981 | up         | 0.010800| 0.215514 |
| hsa_circRNA_104016 | chr5  | exonic       | ERGIC1     | 2.467952 | up         | 0.030440| 0.293641 |
| hsa_circRNA_403982 | chr8  | exonic       | ARHGEF10   | 2.452006 | up         | 0.003123| 0.143279 |
| hsa_circRNA_003140 | chr17 | exonic       | SPRED1     | 2.435171 | up         | 0.005285| 0.173989 |
| hsa_circRNA_092535 | chr11 | exonic       | HBG1       | 11.256796| down       | 0.001087| 0.101860 |
| hsa_circRNA_020964 | chr2  | intronic     | TFRC       | 8.181255 | down       | 0.000064| 0.037264 |
| hsa_circRNA_020960 | chr11 | exonic       | HBG2       | 7.854892 | down       | 0.000932| 0.093134 |
| hsa_circRNA_020960 | chr11 | exonic       | HBG1       | 6.964511 | down       | 0.000880| 0.089225 |
| hsa_circRNA_068601 | chr3  | exonic       | TFRC       | 6.552692 | down       | 0.000444| 0.037264 |
| hsa_circRNA_100436 | chr1  | exonic       | TMCC2      | 6.547989 | down       | 0.002326| 0.134515 |
| hsa_circRNA_092369 | chr1  | exonic       | TMEM56     | 6.166317 | down       | 0.000065| 0.037264 |
| hsa_circRNA_037139 | chr16 | exonic       | HBA2       | 6.042306 | down       | 0.000866| 0.037264 |
| hsa_circRNA_103556 | chr3  | exonic       | TFRC       | 5.446337 | down       | 0.000016| 0.035010 |

FDR, false discovery rate (Benjamini-Hochberg method).

---

**Figure 2**
GO and KEGG analyses according to the host genes of the significantly altered circRNAs. (A) Top gene ontology (GO) terms with the host genes of the up-regulated circRNAs. (B) Top GO terms with the host genes of the down-regulated circRNAs. (C) Top Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways with the host genes of the up-regulated circRNAs. (D) Top KEGG pathways with the host genes of the down-regulated circRNAs.
mediated phagocytosis” and “cell cycle”, respectively (Figures 2C, D).

Preliminary verification of the altered circRNAs

Results of RT-qPCR (Figure 3A) showed that five circRNAs (hsa_circRNA_003986, hsa_circRNA_061346, hsa_circRNA_082319, hsa_circRNA_103399, and hsa_circRNA_003140) were significantly up-regulated and seven (hsa_circRNA_007366, hsa_circRNA_020959, hsa_circRNA_092369, hsa_circRNA_103554, hsa_circRNA_103555, hsa_circRNA_103556, and hsa_circRNA_103557) were significantly down-regulated (Figure 3B).

Prediction of circRNA-miRNA interactions

Bioinformatics analysis revealed five miRNAs associated with each altered circRNA. The top five miRNAs are shown in Figure 4.

Competing endogenous RNA (ceRNA) regulatory network

Figure 5 shows the circRNA-miRNA-mRNA network constructed according to ceRNA regulation. The network includes 314 nodes (eight circRNAs, 184 miRNAs and 122 target genes) and 1862 edges.
GO enrichment and KEGG pathway analyses of the target genes

GO and KEGG analyses showed that the most enriched GO terms include "regulation of cytokine secretion", "mitochondrial intermembrane space", and "4 iron, 4 sulfur cluster binding" (Figure 6A). The most enriched KEGG pathways include "Type II diabetes mellitus" and "GABAergic synapse" (Figure 6B).

Validation of potential biomarkers and their clinical values

The results of RT-qPCR analysis of four circRNAs (hsa_circRNA_061346, hsa_circRNA_092369, hsa_circRNA_103554 and hsa_circRNA_003140) in a larger cohort with (24 ROP infants and 23 controls) showed significantly increased expression of hsa_circRNA_061346 and
significantly decreased expressions of hsa_circRNA_092369 and hsa_circRNA_103554 in the ROP group (Figures 7A–C, P<0.001). However, no significant change was found in expression of hsa_circRNA_003140 (Figure 7D, P>0.05).

To assess the sensitivity and specificity of these three statistically altered circRNAs, we performed ROC curve analysis, and the areas under the curve (AUC) was calculated (Figure 8). The AUC values for hsa_circRNA_061346, hsa_circRNA_092369 and hsa_circRNA_103554 were 0.9239, 0.9239 and 0.8822 respectively (Table 4). Moreover, we determined the cutoff values of hsa_circRNA_061346, hsa_circRNA_092369 and hsa_circRNA_103554 as >0.00047, <0.0002775 and <0.0005235, indicating that diagnostic sensitivities/specificities were 75.00/91.30, 79.17/91.30, and 91.67/73.91 (%), respectively (Table 4).

Discussion

The pathogenesis of ROP, a major cause of childhood blindness, remains unclear. As a novel subtype of ncRNAs, circRNAs serve as promising biomarkers as well as potential targets in a variety of ophthalmic diseases (33). In this study, we identified circRNAs with altered expression levels in ROP.
As a type of non-coding RNAs, circRNAs have no protein-coding capability, alternatively, we may reveal the possible mechanisms of from the host genes of those identified circRNAs. For example, hsa_circRNA_103554 has been validated to be lower expressed in the ROP group (Figure 7), and transferrin receptor (TFRC) is the host gene. Transferrin receptor 1 (TfR1), encoded by TFRC, is a key modulator of iron homeostasis and regulate the pathogenesis in a variety of disorders (34). Deletion of TfR1 inhibits angiogenesis through reduction of mitochondrial complex I in limb ischemia in mice (35). The roles played by hsa_circRNA_103554 and its host gene TFRC in the pathogenesis of hypoxia-induced retinal neovascularization deserve to be further studied.
Using GO analysis, we found that the host genes of the down-regulated circRNAs were enriched in oxygen transport and binding. ROP is induced by hypoxia leading to pathological neovascularization, and oxygen plays an important role in the pathogenesis of ROP (36). An in vivo study indicated that hyperoxia treatment is a useful therapeutic strategy in targeting pathological neovascularization in ischemic retinopathy, and does not have the inflammatory effect related to anti-VEGF therapies (37). A novel oxygen management strategy has been found to decrease the rate of ROP (38). Future studies may be needed to further investigate the roles and mechanisms of circRNAs in oxygen transport in ROP.

It has been shown that circRNA acts as a molecular sponge by binding to miRNAs (39), and in the present study we found interactions between miRNA and the altered circRNAs. Some miRNAs interacted with more than one circRNA, for example, hsa_circRNA_082319 and hsa_circRNA_103556 shared the same miRNA (hsa-miR-149-5p), indicating that these molecules may play a joint regulatory role in the pathological process. Competing endogenous RNA is constituted by coding-protein miRNAs, miRNAs and circRNAs, and regulates gene expressions by competitively binding to common miRNAs (40). The ceRNA regulatory network constructed in the current study identified numerous miRNAs and target genes, and GO and KEGG analyses identified key biological processes such as “regulation of cytokine secretion”. Many cytokines, such as IL-12, IL-17 and IL-23 have been found to have fundamental roles in ocular angiogenesis and ROP pathogenesis (36, 41–43). Therefore, the present results of bioinformatics analysis are consistent with previous findings, and indicate that circRNAs may play a regulatory role in the effect of cytokines on angiogenesis.

Recent studies have also revealed several novel functions of circRNAs in physiological and pathological conditions, such as translation (44, 45), binding proteins (46), and m^5A methylation (47), which deserve to be further studied. We found that hsa_circRNA_061346, hsa_circRNA_092369 and hsa_circRNA_103554 are promising biomarkers in diagnosis of treatment-requiring ROP (AUC > 0.88).

This study provides new findings on the alteration of circRNAs in PBMCs of ROP patients, and suggests several potential biomarkers for ROP diagnosis. However, the study is limited by its small sample size and the lack of ROP patients not requiring treatment. Moreover, there are statistically significant differences in the clinical characteristics, such as gestational age (Table 1), which might affect the results of the assessment. Future clinical studies with larger subjects are needed to verify the clinical values of these potential biomarkers. Besides, in the current study, β-actin has been used as the reference gene for RT-qPCR. Although it has been widely used for normalization in RT-qPCR, numerous studies suggested using multiple reference genes to achieve more convincing results with better stability (48–50). And this should also be considered in future validation studies.

In conclusion, circRNAs were significantly altered in PBMCs of treatment-requiring ROP patients. Three circRNAs were identified and validated to be promising potential biomarkers ROP diagnosis. The significantly expressed circRNAs identified in this study might also be considered as possible therapeutic targets in the treatment of ROP, while further investigations are necessary to explore the exact roles and mechanisms of those specific circRNAs.

**Data availability statement**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: Gene Expression Omnibus database (Accession No. GSE204780).

**Ethics statement**

The studies involving human participants were reviewed and approved by the ethics committee of the Second Xiangya Hospital of Central South University. Written informed
consent to participate in this study was provided by the participants’ legal guardian/next of kin.

**Author contributions**

YZ conceived and designed the study.YL, HZ, QH, WT, YC, and ZW obtained the clinical records, collected, and prepared the samples. YZ, JZ, BL, and SY conducted the data analyses. YL and YZ wrote the manuscript. All authors contributed to the article and approved the final version of the manuscript.

**Funding**

This work was supported by Changsha Science and Technology Project (qk2017075), National Natural Science Foundation of China (No. 81800855, 82171087), Scientific Research Project of Hunan Provincial Health Commission (No. 20207022574) and New Technology Incubation Funds in Ophthalmology.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**References**

1. Lemaitre D, Barjol A, Abdelmassih Y, Faroux C, Martin GC, Metge F, et al. Treatment outside the recommended guidelines for retinopathy of prematurity (ROP): Prevalence, characteristics, and issues. *J Clin Med* (2021) 11:39. doi: 10.3390/jcm1103039
2. Hellstrom A, Smith LE, Dammann O. Retinopathy of prematurity. *Lancet* (2013) 382(9902):1445–57. doi: 10.1016/S0140-6736(13)60178-6
3. Teiada-Pacios P, Zarratea L, Moral M, de la Cruz-Bertolo J. Comparative study of RetCamRetCam II vs. binocular ophthalmoscopy in a screening program for retinopathy of prematurity. *Arch Soc Esp Oftalmol* (2015) 90(8):373–8. doi: 10.1016/j.aso.2015.02.008
4. Tan W, Li B, Wang Z, Zou J, Ji Y, Yoshida S, et al. Novel potential biomarkers for retinopathy of prematurity. *Front Med (Lausanne)* (2022) 9:840030. doi: 10.3389/fmed.2022.840030
5. Seery CW, Betesh S, Guo S, Zarbin MA, Bhagat N, Wagner RS. Update on the use of anti-VEGF drugs in the treatment of retinopathy of prematurity. *J Pediatr Ophthalmol Strabismus* (2020) 57(6):351–62. doi: 10.3928/1913-8028-20200824-02
6. Del Portillo MC, Navarro PI, Duran D, Serrano JC. Effect of laser photocoagulation, antiangiogenic therapy or a combined treatment on refractive outcomes of newborns with ROP. *Eur J Ophthalmol* (2022) 12:3067211221078668. doi: 10.1177/123280721221078668
7. Lasda E, Parker R. Circular RNAs: diversity of form and function. *RNA* (2014) 20(12):1829–42. doi: 10.1261/rna.047126.114
8. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* (2013) 495(7443):334–8. doi: 10.1038/nature12012
9. Lu H, Yang Y, Kuang D, Liu P, Yang J. Expression profile of circRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis. *BMC Med Genomics* (2015) 15(1):77. doi: 10.1186/s12920-015-0122-9
10. Allegra A, Cicero N, Tonacci A, Musolino C, Gangemi S. Circular RNA as a novel biomarker for diagnosis and prognosis and potential therapeutic targets in multiple myeloma. *Cancers (Basel)* (2022) 14(7):1700. doi: 10.3390/cancers14071700
11. Zhang Z, Guo R, Wang Y, Huang H, Liu J, Wang C, et al. Diagnostic value of circRNAs as effective biomarkers in human cardiovascular disease: an updated meta-analysis. *Int J Med Sci* (2022) 19(3):446–59. doi: 10.7150/ijms.67094
12. Hansen TB, Jensen TL, Clausen BH, Bramsen JB, Binsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. *Nature* (2013) 495(7443):384–8. doi: 10.1038/nature11993
13. Liu Y, Khan S, Li L, Ten Hagen TLM, Fahhabi M. Molecular mechanisms of thyroid cancer: A competing endogenous RNA (ceRNA) point of view. *BioMed Pharmacother* (2022) 146:112251. doi: 10.1016/j.biopha.2021.112251
14. Hanineva A, Park KS, Wang JJ, DeAngelis MM, Farkas MH, Zhang SX. Emerging roles of circular RNAs in retinal diseases. *Neural Regener Res* (2022) 17(19):1875–80. doi: 10.4103/1673-5734.335691
15. He H, Zhang J, Gong W, Liu M, Liu H, Li X, et al. Involvement of CircRNA expression profile in diabetic retinopathy and its potential diagnostic value. *Front Genet* (2022) 13:833573. doi: 10.3389/fgene.2022.833573
16. Wu Z, Liu B, Ma Y, Chen H, Wu J, Wang J. Discovery and validation of has_circ_0041953 as a potential biomarker for proliferative diabetic retinopathy in human blood. *Acta Ophthalmol* (2021) 99(3):306–13. doi: 10.1111/aos.14585
17. Jiang Y, Xiao F, Wang L, Wang T, Chen L. Has_circ_0099198 facilitates the progression of retinoblastoma by regulating miR-1287/LRP6 axis. *Exp Eye Res* (2021) 206:108529. doi: 10.1016/j.exer.2021.108529
18. Huang J, Chen M, Xu K, Zhou R, Zhang S, Zhao C. Microarray expression profile and functional analysis of circular RNAs in choroidal neovascularization. *J Biomed Res* (2019) 34(1):67–74. doi: 10.7555/JBR.33.20190063
19. Li X, Wang J, Qian H, Wu Y, Zhang Z, Hu Z, et al. Serum exosomal circular RNA expression profile and regulatory role in proliferative diabetic retinopathy. *Front Genet* (2021) 12:719312. doi: 10.3389/fgene.2021.719312
20. Yao MD, Jiang Q, Ma Y, Zhu Y, Zhang QY, Shi ZH, et al. Targeting circular RNA-MET for anti-angiogenesis treatment via inhibiting endothelial tip cell specialization. *Mol Ther* (2022) 30(3):1252–64. doi: 10.1016/j.ymthe.2021.01.012
21. Deng Y, Li S, Li S, Yu C, Huang D, Chen H, et al. CircPDE4B inhibits retinal pathological angiogenesis via promoting degradation of HIF-1alpha though targeting miR-181c. *IUBMB Life* (2020) 72(9):1920–9. doi: 10.1002/iub.2307
22. Cao M, Zhang L, Wang H, Zeng H, Peng Y, Zou J, et al. Identifying circRNA-associated-eRNA networks in retinal neovascularization in mice. *Int J Mol Sci* (2019) 16(10):1356–65. doi: 10.3390/ijms.16053149
23. Werfel S, Nothjunge S, Schwarzmayer T, Strom TM, Mettinger T, Engelhardt S. Characterization of circular RNAs in human, mouse and rat hearts. *J Mol Cell Cardiol* (2016) 98:103–7. doi: 10.1016/j.yjmcc.2016.07.007
24. Silveira RC, Fortes Filho JB, Prociunay RS. Assessment of the contribution of cytokine plasma levels to detect retinopathy of prematurity in very low birth weight infants. *Invest Ophthalmol Vis Sci* (2011) 52(3):1297–301. doi: 10.1167/ioscience.10-6279
25. Gao X, Wang YS, Li QX, Hou HY, Su JB, Yao LB, et al. Macrophages promote vascularogenesis of retinal neovascularization in an oxygen-induced retinopathy model in mice. Cell Tissue Res (2016) 364(3):599–610. doi: 10.1007/s00441-015-2353-y

26. Klotsche-von Ameln A, Sprott D. Harnessing retinal phagocytes to combat pathological neovascularization in ischemic retinopathies. Pflugers Arch (2022) 474(6):575–90. doi: 10.1007/s00424-022-02695-7

27. Sen P, Kempainen E, Orecsi M. Perspectives on systems modeling of human peripheral blood mononuclear cells. Front Mol Biosci (2017) 4:96. doi: 10.3389/fmolb.2017.00096

28. Zavarska AE, Mycho MP, Selmaï J, Raine CS, Selmaï KW. Multiple sclerosis: circRNA profile defined reveals links to b-cell function. Neurotrophin Neuroinflamm (2021) 8(5):e1041. doi: 10.1212/NXI.0000000000100141

29. Luo Q, Li X, Fu B, Zhang L, Fang L, Qing C, et al. Expression profile and diagnostic value of circRNAs in peripheral blood from patients with systemic lupus erythematosus. Mol Med Rep (2021) 23(1):1. doi: 10.3892/mmr.2020.11639

30. ICCROP. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol (2005) 123(7):991–9. doi: 10.1001/archophth.123.7.991

31. Zhou Y, Xu Y, Zhang X, Zhao P, Gong X, He M, et al. Plasma metabolites in treatment-requiring retinopathy of prematurity: Potential biomarkers identified by metabolomics. Exp Eye Res (2020) 199:108198. doi: 10.1016/j.exer.2020.108198

32. Wang Z, Xu P, Chen B, Zhang Z, Zhang C, Qian Z, et al. Identifying circRNA-associated-miRNA networks in the hippocampus of Abetal-42-induced Alzheimer's disease-like rats using microarray analysis. Aging (Albany NY) (2018) 10(4):775–88. doi: 10.3892/mmr.2020.11639

33. Zhang C, Hu J, Yu Y. CircRNA is a rising star in researches of oculardiseases. Front Cell Dev Biol (2020) 8:850. doi: 10.3389/fcell.2020.00850

34. Huang N, Wei Y, Cheng Y, Wang X, Wang Q, Chen D, et al. Iron metabolism protein transferrin receptor 1 involves in cervical cancer progression by affecting gene expression and alternative splicing in HeLa cells. Genes Genomics (2022) 44(6):637–50. doi: 10.1007/s13258-021-01205-w

35. Okuno K, Naito Y, Yamamura S, Sawada H, Asakura M, Tamaguchi T, et al. Haploinsufficiency of transferrin receptor 1 impairs angiogenesis with reduced mitochondrial complex I in mice with limb ischemia. Sci Rep (2019) 9(1):13658. doi: 10.1038/s41598-019-49983-4

36. Faria-Sano-Martin M, Guimarães H, Marques-Neves C, Bicho M. Retinopathy of prematurity: contribution of inflammatory and genetic factors. Mol Cell Biochem (2022) 477(6):1739–63. doi: 10.1007/s10100-022-04394-4

37. Liu H, Zhang W, Xu Z, Caldwell RW, Caldwell RB, Brooks SE. Hypoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway. Invest Ophthalmol Vis Sci (2013) 54(2):918–31. doi: 10.1167/iovs.12-11291

38. Srivastava B, Malcolm K, Clark RH, Kupke KG. Effect of a novel oxygen saturation targeting strategy on mortality, retinopathy of prematurity, and bronchopulmonary dysplasia in neonates born extremely preterm. J Pediatr (2021) 234:33–7.e3. doi: 10.1016/j.jpeds.2021.03.007

39. Han JJ, Wang XQ, Zhang XA. Functional interactions between lncRNAs/ circRNAs and miRNAs: Insights into rheumatoid arthritis. Front Immunol (2022) 13:830317. doi: 10.3389/fimmu.2022.810317

40. Mao M, Zhang J, Xiang Y, Gong M, Deng Y, Ye D. Role of exosomal competitive endogenous RNA (ceRNA) in diagnosis and treatment of malignant tumors. Bioengineered (2022) 13(5):12156–68. doi: 10.1080/21659979.2022.2073130

41. Zhou Y, Yoshida S, Kubo Y, Kobayashi Y, Nakama T, Yamaguchi M, et al. Interleukin-12 inhibits pathological neovascularization in mouse model of oxygen-induced retinopathy. Sci Rep (2016) 6:28140. doi: 10.1038/srep28140

42. Li N, Gao S, Wang J, Zhu Y, Shen X. Anti-apoptotic effect of interleukin-17 in a mouse model of oxygen-induced retinopathy. Exp Eye Res (2019) 187:107743. doi: 10.1016/j.exer.2019.107743

43. Cai Y, Tan W, Shen X, Zhu Y, Gao Y, Sui A, et al. Neutralization of IL-23 depresses experimental ocular neovascularization. Exp Eye Res (2016) 146:242–51. doi: 10.1016/j.exer.2016.02.008

44. Pamunuri NR, Bariko O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Translation of CircRNAs. Mol Cell (2017) 66(1):9–21.e7. doi: 10.1016/j.molcel.2017.02.021

45. Lu Y, Li Z, Lin C, Zhang J, Shen Z. Translation role of circRNAs in cancers. J Clin Lab Anal (2021) 35(7):e23866. doi: 10.1002/jcla.23866

46. Holst LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wöllert W, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun (2016) 7:12429. doi: 10.1038/ncomms12429

47. Zhang L, Hou C, Chen G, Gao Y, Yuan W, Yin D, et al. The role of N(6)-methyladenosine (m(6)A) modification in the regulation of circRNAs. Mol Cancer (2020) 19(1):105. doi: 10.1186/s12943-019-1112-1

48. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kuhtka M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem (2009) 55(4):611–22. doi: 10.1373/clinchem.2008.112797

49. Bantula M, Arismendi E, Picado C, Mullol J, Roa-Carrera J, Tubita V. Reference gene validation for RT-qPCR in PBMCs from asthmatic patients with or without obesity. Methods Protoc (2022) 5(1):35. doi: 10.3390/mpsc0030035

50. Verma P, Sharma A, Sodhi M, Tiwari M, Vivek P, Kataria RS, et al. Identification of internal reference genes in peripheral blood mononuclear cells of cattle populations adapted to hot arid normoxia and cold arid hypoxia environments. Front Genet (2021) 12:730599. doi: 10.3389/fgene.2021.730599